GlassScriptPhysician profile
Rosa L King
NPI 1346393378
$1,374.71
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $69.35 · 2022: $381.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $244.97 | 2019 | |
| Silk Road Medical, INC. | $150.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.04 | 2019-2022 | |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Neurocrine Biosciences, INC. | $125.00 | 2019 | |
| Glaxosmithkline, LLC. | $125.00 | 2019 | |
| Boston Scientific Corporation | $106.40 | 2019 | |
| Gilead Sciences, INC. | $97.62 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.49 | 2022 | |
| Novo Nordisk INC | $77.86 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54.99 | 2022 | |
| Lilly USA, LLC | $17.03 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.31 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rosa King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.